Centessa Pharmaceuticals plc
CNTA
Rang in Aktien
#2955
Centessa Pharmaceuticals plc operates as a clinical-stage pharmaceutical... Centessa Pharmaceuticals plc operates as a clinical-stage pharmaceutical enterprise focused on discovering, developing, and ultimately providing therapeutic solutions to patients. The company's most advanced product candidates include Lixivaptan, a small molecule inhibitor of the vasopressin V2 receptor, which is currently undergoing Phase III clinical evaluation for treating autosomal dominant polycystic kidney disease. Additionally, SerpinPC, an activated protein C inhibitor, is progressing through Phase IIa clinical development for the management of hemophilia A and B. Centessa's pipeline also features several emerging assets in the clinical proof-of-concept stage. These comprise LB101 (a PD-L1xCD47 LockBody) and LB201 (a PD-L1xCD3 LockBody), both engineered to selectively activate potent CD47 and CD3 effector functions while minimizing systemic side effects. Another molecule, ZF874, is a small molecule pharmacological chaperone in Phase I studies, designed to correct the misfolding of the Z variant of alpha-1-antitrypsin, thus addressing alpha-1-antitrypsin deficiency. Furthermore, MGX292, a recombinant modified BMP9 replacement protein, aims to rectify the deficient BMP9 signaling implicated in Pulmonary Arterial Hypertension. The company is also developing OX2R Agonists, which are selective orexin receptor 2 agonists (available as oral and intranasal formulations) intended to directly target the underlying pathophysiology of orexin neuron loss in Narcolepsy Type 1 by leveraging structural insights. Beyond these, Centessa is exploring further clinical proof-of-concept compounds. CBS001, an anti-LIGHT antibody, is being investigated for inflammatory and fibrotic diseases due to its preferential binding to the inflammatory membrane form of LIGHT. Lastly, CBS004 is a humanized monoclonal antibody specifically targeting BDCA2, a protein found exclusively on plasmacytoid dendritic cells, with potential utility in conditions such as systemic sclerosis, systemic lupus erythematosus, and other autoimmune disorders. Centessa Pharmaceuticals plc was established in 2020 and is headquartered in Altrincham, United Kingdom.
Aktienkurs
$40.50
Zuletzt synchronisiert: 2026-06-29
Marktkapitalisierung
$6.22B
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
75.93%
Land
GB
Handel Centessa Pharmaceuticals plc (CNTA)
Kategorie
Healthcare
Gewinn für Centessa Pharmaceuticals plc (CNTA)
Gewinn im Mar 2026 TTM: $-249.37M
Laut den aktuellen Finanzberichten von Centessa Pharmaceuticals plc betragen die aktuellen Gewinne des Unternehmens $-249.37M. Im Jahr 2023 erzielte das Unternehmen einen Gewinn von $-176.14M, eine Steigerung gegenüber dem Gewinn im Jahr 2022, der $-216.95M betrug. Die auf dieser Seite angezeigten Gewinne sind die Gewinne vor Zinsen und Steuern, auch bekannt als EBIT.
Gewinnverlauf von Centessa Pharmaceuticals plc von 2019 bis 2026
Gewinn am Ende jedes Jahres
| Jahr | Gewinn | ändert |
|---|---|---|
| 2026 (TTM) | $-249.37M | 7.06% |
| 2024 | $-232.91M | 32.23% |
| 2023 | $-176.14M | -18.81% |
| 2022 | $-216.95M | -43.17% |
| 2021 | $-381.79M | 3,480.47% |
| 2020 | $-10.66M | 110.69% |
| 2019 | $-5.06M | 0.00% |
Gewinn ähnlicher Unternehmen oder Konkurrenten
| Unternehmen | Gewinn | Gewinnunterschied | Land |
|---|---|---|---|
| $5.27B | -2,215.32% |
US
|
|
| $-3.09B | 1,137.94% |
US
|
|
| $-4.02B | 1,510.56% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -882.24% |
NL
|
